China Securities Co., Ltd.: Q3 NAV drawdown weighs on scale; contrarian subscriptions shore up mutual fund shares
Looking ahead, whether the company can serve its existing clients well and clearly explain performance may become even more important.
China Securities Co., Ltd. released a research report stating that the decline in mutual fund scale in Q3 was mainly due to NAV drawdowns, while industry shares continued to increase, holder behavior remained relatively stable, and funds did not leave mutual funds as a whole. Funds adjusted direction within the industry, with inflows into tool-based products and stable-type products being relatively evident, while active equity remained in a contraction process. The data changes in Q3 may, to some extent, reflect an adjustment in the growth model of mutual funds: amid the tech sector correction, new issuance declined, shares grew, tool-based products saw net fund inflows, and fixed-income products absorbed incremental capital, with the industry's focus gradually shifting from selling products to managing client accounts. Looking ahead, whether existing clients can be well served and performance clearly explained may become more important.
China Securities Co., Ltd.'s main views are as follows:
In Q3, fund shares across the entire market grew quarter-on-quarter, and the scale decline came more from NAV drawdowns; funds did not leave mutual funds as a whole. The most noteworthy change may be the simultaneous contraction of active equity in issuance, subscriptions/redemptions, and existing scale, while equity ETFs tracking declining indices showed net fund inflows.
1. Active equity under simultaneous pressure in issuance, subscriptions/redemptions, and existing scale. Calculating active equity as the combined total of ordinary equity funds and equity-biased hybrid funds, new issuance in Q3 was RMB34.588 billion, a quarter-on-quarter decrease of RMB49.576 billion; net redemptions were 92.952 billion shares, and existing scale fell 19.87% quarter-on-quarter, with issuance, subscriptions/redemptions, and scale all moving in the same direction.
2. ETFs tracking declining indices mostly showed net fund inflows, while those tracking rising indices mostly saw net outflows, with rebalancing characteristics relatively evident. For example, the SSE STAR 50 Constituents Index ETF saw net inflows of RMB87.051 billion, while the index fell 28.03% over the same period; the Hong Kong Innovative Drug HKD Index rose 31.03%, and funds saw net outflows of RMB7.745 billion. Overall, equity ETFs saw net subscriptions of 340.194 billion shares amid the A-share market's oscillating decline, making them the main vehicle for equity fund inflows. Equity ETFs are often important tools for allocation-type funds, buying on declines and redeeming on rises, which may be difficult to understand from a single investor's perspective but has its own logic from a portfolio rebalancing perspective. ETF holdings are transparent and trading is convenient, making them more easily used as tools to adjust positions on both the upside and downside.
3. Manager scale increments concentrated in fixed income and money market products. Most managers with the largest quarterly increments relied on money market or fixed-income products. During periods of declining bond yields, the attractiveness of stable-type products increased.
ETF fund inflows include both portfolio rebalancing factors and passive allocation demand during market adjustment periods; the contraction of active equity reflects both the impact of market adjustments and aspects of the industry itself that need improvement. During market adjustment periods, certainty tends to receive more attention.
Risk warnings: uncertainty of market price fluctuations, uncertainty of corporate earnings forecasts, and technological updates and iterations.
Related Articles

HK Stock Market Move | INNOVENT BIO (01801) rose over 3% intraday as seven innovative products, including XinerMei, were successfully included in the National Reimbursement Drug List.

HK Stock Market Move | Chip stocks rise against the market trend as the U.S. plans to tighten AI chip restrictions, with domestic substitution and self-reliance becoming an inevitable trend.

Citi: Raises Dajin Heavy Industry (01081) target price to HK$34, reiterates "Buy" rating
HK Stock Market Move | INNOVENT BIO (01801) rose over 3% intraday as seven innovative products, including XinerMei, were successfully included in the National Reimbursement Drug List.

HK Stock Market Move | Chip stocks rise against the market trend as the U.S. plans to tighten AI chip restrictions, with domestic substitution and self-reliance becoming an inevitable trend.

Citi: Raises Dajin Heavy Industry (01081) target price to HK$34, reiterates "Buy" rating






